Compare American International Group Inc (AIG) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American International Group Inc vs Amylx Pharmaceuticals Inc — how do they compare? American International Group Inc trades at $79.57 (market cap $42.98B), while Amylx Pharmaceuticals Inc trades at $17.97 (market cap $2.02B). The key difference: American International Group Inc is far larger — about 21.3× Amylx Pharmaceuticals Inc's market cap, and American International Group Inc pays a 2.47% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AIG | AMLX | |
|---|---|---|
Market Cap | $42.98B | $2.02B |
Sector | Financials | Health |
52-Week High | $86.59 | $18.70 |
52-Week Low | $71.89 | $6.98 |
Enterprise Value | $50.68B | $1.75B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $81.06, up 2.1% today, showing strong momentum with three consecutive quarterly earnings beats. The stock is supported by bullish technical signals and a consensus price target of $88.13. Recent executive appointments and the acquisition of Everest Colombia signal strategic growth initiatives. Revenue stabilized around $26.8B in 2025 with net income margin improving to 11.88%.
Outlook remains positive with earnings growth and expansion in Latin America offering upside potential. Risks include catastrophe exposure and competitive pressures. Analysts are predominantly neutral with 58.5% Hold ratings, suggesting cautious optimism amid solid fundamentals.
AMLX trades at $17.97, down 1.64% today, with strong analyst support showing 91% buy ratings and a $30.50 consensus price target representing 70% upside potential. The stock shows bullish technical momentum with positive moving average signals, though RSI levels suggest some overbought conditions. Recent earnings showed mixed results with a Q1 2026 miss after two previous beats, while the company continues advancing its pipeline with Phase 3 data for avexitide expected in Q3 2026.
Despite negative profitability metrics and cash burn, AMLX maintains strong institutional confidence with 11 analysts covering the stock. The key catalyst remains the upcoming Phase 3 avexitide readout, though risks include ongoing class action litigation and the company's negative cash flow from operations. Current valuation at 7.31x book value reflects optimism around pipeline assets rather than current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
